Following a late-stage clinical trial where Merck and Moderna reported their mRNA vaccine, named intismeran autogene, successfully delayed the return and spread of melanoma, researchers are debating whether mRNA technology can be successfully applied to other cancers. Karen Knudsen, CEO of the Parke